In therapeutic pre-clinical models, vaccination with short MHC class I binding peptides hinders CTL priming and induce tolerance, whereas combination with CD40 agonist antibody infusion or DC stimulated in vitro with antigen-specific CD4+ T cell resulted in CTL-based anti-tumor immune response (2). The gene discussed is CD4; the disease is neoplasm.